Regeneron Pharmaceuticals Inc (NASDAQ:REGN), a leader in biotechnology, focuses on developing treatments for eye diseases, cardiovascular conditions, cancer, and inflammation.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron (REGN) has been on a downward spiral lately with significant selling pressure. After declining 11.3% over the past four weeks, the stock looks well positioned for a trend reversal as it ...

On June 10, 2025, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) received a ‘Hold’ rating from Wells Fargo, which set the company’s stock price target at $580. REGN is one of the 7 52-week ...

The overall sentiment of these big-money traders is split between 36% bullish and 31%, bearish. Out of all of the special options we uncovered, 10 are puts, for a total amount of $724,710, and 12 are ...

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive ...

Regeneron purchased the pioneering company for $256 million at bankruptcy auction with the intent of using its genomic data to fuel drug discovery, the company said in a Monday statement.